<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05797922</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWP16001109</org_study_id>
    <nct_id>NCT05797922</nct_id>
  </id_info>
  <brief_title>To Evaluate the Effect of Food on the Safety and PK Characteristics of DWP16001 in Healthy Adult Volunteers</brief_title>
  <official_title>A Phase 1 Clinical Trial to Evaluate the Effect of Food on the Pharmacokinetics and Safety of DWP16001 After Administration in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the effect of food on the pharmacokinetics and safety of DWP16001&#xD;
      after oral administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design is A randomized, Open-label, Oral, Single-dose, Two-way crossover study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2023</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-t of DWP16001</measure>
    <time_frame>0 to 72 hours</time_frame>
    <description>AUC0-t of DWP16001</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of DWP16001</measure>
    <time_frame>0 to 72 hours</time_frame>
    <description>Cmax of DWP16001</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>DWP16001 to Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A: Fasting in Period 1 / Fed in Period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DWP16001 to Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B: Fed in Period 1 / Fasting in Period 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP16001</intervention_name>
    <description>DWP16001 0.3mg</description>
    <arm_group_label>DWP16001 to Group A</arm_group_label>
    <arm_group_label>DWP16001 to Group B</arm_group_label>
    <other_name>DWP16001 0.3mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A person who has decided to participate voluntarily and agreed in writing prior to the&#xD;
             screening procedure after understanding the detailed explanation of this clinical&#xD;
             trial.&#xD;
&#xD;
          2. A person who is 19 years of age or more at the time of screening.&#xD;
&#xD;
          3. Those with a weight of 50.0 kg or more and a body mass index (BMI) of 18.0 kg/m2 or&#xD;
             more and 30.0 kg/m2 or less.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A person who has a genetic problem such as galactose intolerance, Lapp lactase&#xD;
             deficiency or glucose-galactose malabsorption.&#xD;
&#xD;
          2. A person who has a history of gastrointestinal surgery/disease, such as Crohn's&#xD;
             disease, ulcer, acute or chronic pancreatitis, which may affect the absorption of drug&#xD;
             for clinical trials. (Except for simple appendectomy or hernia surgery)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chungbuk National University Hospital</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungbuk National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daewoong Pharmaceutical</last_name>
    <phone>080-550-8308</phone>
    <email>yoonhye@daewoong.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Chungbuk</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Gi Hwang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 21, 2023</study_first_submitted>
  <study_first_submitted_qc>April 3, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>April 3, 2023</last_update_submitted>
  <last_update_submitted_qc>April 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

